One year's treatment with propranolol after myocardial infarction: Preliminary report of Norwegian multicentre trial

British Medical Journal (Clinical research ed.)

Volumn 284, Issue 6310, 1982, Pages 155-160

  Hansteen, V ^a   Knudsen, K ^a   Eika, C ^a   MoINICHEN E ^b   Lorentsen, E ^h   Andersen, A ⁱ   Strom O ^c   Soiland K ^c   Dyrbekk, D ^c   Refsum, A M ^d   Tromsdal, A ^j   Bakken, J ^e   Smith, P ^f   Hoff, P I ^g  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c VESTFOLD HOSPITAL TRUST   (Norway)

^d Section for Foot and Ankle Surgery   (Norway)

^e Central Hospital of Opland ^*  (Norway)

^f Central Hospital of Nordland ^*  (Norway)

^g Deakoness Hospital ^*  (United Kingdom)

^h Central Hospital of Akershus ^*  (Norway)

ⁱ Central Hospital of Trondheim ^*  (United Kingdom)

^j City of Trondheim   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPRENOLOL; PRACTOLOL; PROPRANOLOL; TIMOLOL; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRONCHOSPASM; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG COMPARISON; DRY EYE; FATALITY; HEART; HEART FAILURE; HEART INFARCTION; HUMAN; HYPOTENSION; INTERMITTENT CLAUDICATION; LARGE INTESTINE; MUSCLE; NIGHTMARE; ORAL DRUG ADMINISTRATION; PERIPHERAL VASCULAR SYSTEM; PREVENTION; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYSTEM; SLEEP DISORDER; SUDDEN DEATH; THERAPY; VERTIGO;

ADULT; AGED; CLINICAL TRIALS; DEATH, SUDDEN; DOUBLE-BLIND METHOD; FEMALE; HEART ARREST; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPRANOLOL; RANDOM ALLOCATION; TIME FACTORS;

EID: 0020059988     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.284.6310.155     Document Type: Article

References (30)

1. Pell S, d'Allonzo CA. Immediate and five-year survival of employed men with a first myocardial infarction. N Engl J Med 1964;270:915-22.
2. Norris RM, Mercer CI. Long term prognosis following treatment in a coronary care unit. Aust NZ J Med 1973; i:31-33.
3. Denborough MA, Lowell RR, Nestel PJ, Goble AJ. Arrhythmias and late sudden death after myocardial infarction. Lancet 1968; i:386-88.
4. The Coronary Drug Project Group. The importance of the electrocardiogram after myocardial infarction. Ann Intern Med 1972; 77:677-89.
5. Vedin JA, Wilhelmson CE, Elmfeldt D, Tibblin G, Wilhelmsen L, Werk⊘ L. Sudden death: identification of high risk groups. Am Heart J 1973;68:124-32.
6. Kuller L, Lilienfeld A, Fisher R. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 1966;34:1056-63.
7. Wilhelmsson C, Vedin JA, Wilhelmsen L, Tibblin G, Werk⊘ L. Reduction of sudden deaths after myocardial infarction by treatment with alprenolol; preliminary results. Lancet 1974; ii:1157-60.
8. Ahlmark G, Saetre H. Long-term treatment with beta-blockers after myocardial infarction. Europ J Clin Pharmacol 1976; 10:77-83.
9. Green KG, Chamberlain DA, Fulton RM, et al. Multicentre International Study: Improvement in prognosis of myocardial infarction by long-term beta-adrenoceptor blockade using practolol. Br Med J 1975; iii:735-40.
10. Green KG, Chamberlain DA, Fulton RM, et al. Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade: Multicentre International Study: Supplementary Report. Br Med J 1977; ii:419-21.
11. Andersen MP, Frederiksen J, Jiirgensen HJ, et al. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction: Preliminary results. Lancet 1979; ii:865-7.
12. The Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304:801-7.
13. Reynolds JL, Whitlock AML. Effects of beta-adrenergic receptor blocker in myocardial infarction for one year from outset. Br Heart J 1972;34: 252-9.
14. Barber JM, Boyle DM, Chaturverdi NC, Singh N, Walsh MJ. Practolol in acute myocardial infarction. Acta Med Scand 1975; suppl 587 : 213-9.
15. Baber NS, Wainwright Evans D, Howitt G, et al. Multicentre post-infarction trial of propranolol in 49 in the United Kingdom, Italy and Yugoslavia. Br Heart J 1980; 44:96-100.
16. Wilox RG, Roland JM, Banks DC, Hampton JR, Mitchell JRA. Randomised trial comparing propranolol with atenolol and placebo in immediate treatment of suspected myocardial infarction. Br Med J 1980; 281:885-8.
17. WHO. Ischaemic heart disease registers. Report of the fifth working group. Copenhagen: WHO, 1971.
18. Skjaeggestad Ø, Hansteen V, Sivertssen E. Acute myocardial infarction in a medical intensive care unit during a 3-year period 1977-9. The correlation in 744 patients between prognosis and a grading of infarct size. Journal of Oslo City Hospital, in press.
19. Lown B, Fakhro AM, Hood WB, Jr, Thorn GW. The coronary care unit, new perspectives and directions. JAMA 1967;199:188-93.
20. Fellowship of Postgraduate Medicine: Ten years of propranolol. Postgrad Med J 1976; 52, suppl 4 : 1-192.
21. Coltart DJ, Meldrum SJ, Hamer J. The effect of propranolol on the human and canine transmembrane action potential. Br J Pharmacol 1970; 40:148-62.
22. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Introduction and design. Br J Cancer 1976;34:585-611.
23. Frieman JA, Chalmers TC, Smith HJ, Kubler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized controlled study. Survey of 71 “negative trials”. N Engl J Med 1978; 299:690-4.
24. Woosley RK, Kornhauser D, Smith R, et al. Suppression of chronic ventricular arrhythmias with propranolol. Circulation 1979; 60:819-27.
25. Shand DG. Individualization of propranolol therapy. Med Clin North Am 1974;58:1063-9.
26. Alderman EL, Coltart J, Wettach GE, Harrison DC. Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med 1974; 81 :625-7.
27. Julian DG. The significance and management of ventricular arrhythmias. J R Coll Physicians London 1980;14:17-21.
28. Baber NS. Clinical experience with beta adrenergic blocking agents in myocardial ischaemia: A dilemma and a challenge. Pharmacol Ther 1981;13:285-320.
29. Hampton JR. Presentation and analyses of the results of clinical trials in cardiovascular disease. Br Med J 1981; 282:1371-3.
30. Mitchell JRA. Timolol after myocardial infarction: an answer or a new set of questions? Br Med J 1981; 282: 1965-70.